The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Integrated Molecular Characterization of Uterine Carcinosarcoma
Open accessAbstract
Summary We performed genomic, epigenomic, transcriptomic and proteomic characterizations of uterine carcinosarcomas (UCSs). Cohort samples had extensive copy number alterations and highly recurrent somatic mutations. Frequent mutations were found in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7 and KRAS, similar to endometrioid and serous uterine carcinomas. Transcriptome sequencing identified a strong epithelial-to-mesenchymal transition (EMT) gene signature in a subset of cases that was attributable to epigenetic alterations at microRNA promoters. The range of EMT scores in UCS was the largest amongst all tumor types studied via The Cancer Genome Atlas. UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EMT features. Multiple somatic mutations and copy number alterations in genes that are therapeutic targets were identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Self-citationIntegrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 3×
“SMGs for other tumor types were based on www.tumorportal.org (Lawrence et al., 2014).”
BackgroundMethodSelf-citationAbsolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationWHO classification of tumours of female reproductive organs
Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014) · International Agency for Research on Cancer eBooks · Cited by 1,966
Pan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
Self-citationByers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationEpithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A., Whittaker, S., Kryukov, G. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 912
Self-citationSynthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 607
Self-citationARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · cited 1×
“A number of reports indicate that inactivation of chromatin-remodeling genes such as ARID1A and CHD4 results in susceptibility to various targeted therapies including PARP and EZH2 inhibition (Bitler et al., 2015; Pan et al., 2012; Shen et al., 2015).”
BackgroundSelf-citationARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
Wu, J. N., & Roberts, C. W. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0361 · Cited by 456
Epithelial-mesenchymal transition
Radisky, D. C. (2005) · Journal of Cell Science · doi:10.1242/jcs.02552 · Cited by 417
The epithelial–mesenchymal transition (EMT) phenomenon
Savagner, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq292 · Cited by 413
Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
McCluggage, W. G. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.5.321 · Cited by 379
Thompson, L., Chang, B., & Barsky, S. H. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199603000-00003 · Cited by 365
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Self-citationThe emerging roles of ARID1A in tumor suppression
Wu, R.-C., Wang, T.-L., & Shih, I.-M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28411 · Cited by 261
Hennessy, B. T., Lu, Y., Gonzalez-Angulo, A. M., Carey, M. S., Myhre, S., Ju, Z., Davies, M. A., Liu, W., Coombes, K., Meric-Bernstam, F., et al. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9055-y · Cited by 241
Self-citationZhao, S., Bellone, S., Lopez, S., Thakral, D., Schwab, C., English, D. P., Black, J., Cocco, E., Choi, J., Zammataro, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614120113 · Cited by 228
Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Brinton, L. A., Felix, A. S., McMeekin, D. S., Creasman, W. T., Sherman, M. E., Mutch, D., Cohn, D. E., Walker, J. L., Moore, R. G., Downs, L. S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.02.023 · Cited by 216
Self-citationTherapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer
Cortez, M. A., Valdecanas, D., Zhang, X., Zhan, Y., Bhardwaj, V., Calin, G. A., Komaki, R., Giri, D. K., Quini, C. C., Wolfe, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.79 · Cited by 196
Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada, H., Enomoto, T., Fujita, M., Yoshino, K., Nakashima, R., Kurachi, H., Haba, T., Wakasa, K., Shroyer, K. R., Tsujimoto, M., et al. (1997) · PubMed · Cited by 193
Kounelis, S., Jones, M. W., Papadaki, H., Bakker, A., Swalsky, P., & Finkelstein, S. D. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90394-x · Cited by 184
Prognostic Features of Surgical Stage I Uterine Carcinosarcoma
Ferguson, S. E., Tornos, C., Hummer, A., Barakat, R. R., & Soslow, R. A. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181161ba3 · Cited by 174
Self-citationJones, S., Stransky, N., McCord, C. L., Cerami, E., Lagowski, J., Kelly, D., Angiuoli, S. V., Sausen, M., Kann, L., Shukla, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6006 · Cited by 166
Self-citationFujii, H., Yoshida, M., Gong, Z. X., Matsumoto, T., Hamano, Y., Fukunaga, M., Hruban, R. H., Gabrielson, E., & Shirai, T. (2000) · PubMed · Cited by 153
Pan, M., Hsieh, H.-J., Dai, H., Hung, W.-C., Li, K., Peng, G., & Lin, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.287037 · Cited by 121
In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas
McConechy, M. K., Hoang, L. N., Chui, M. H., Senz, J., Yang, W., Rozenberg, N., Mackenzie, R., McAlpine, J. N., Huntsman, D. D., Clarke, B. A., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.18 · Cited by 104
Probing the Fifty Shades of EMT in Metastasis
Li, W., & Kang, Y. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.01.001 · Cited by 98
Makker, V., Recio, F. O., Ma, L., Matulonis, U. A., Lauchle, J., Parmar, H. R., Gilbert, H., Ware, J. A., Zhu, R., Lu, S., et al. (2016) · Cancer · doi:10.1002/cncr.30286 · Cited by 93
Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
Miller, R. E., Brough, R., Bajrami, I., Williamson, C. T., McDade, S. S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H. N., Natrajan, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0554 · Cited by 89
Oncogenic RIT1 mutations in lung adenocarcinoma
Ah, B., Imielinski, M. B., Duke, F. F., Wala, J. A., Kaplan, N. O., Gx, S., Andres, D., & Meyerson, M. M. (2014) · Oncogene · doi:10.1038/onc.2013.581 · Cited by 87
Self-citationPathologic and molecular features of uterine carcinosarcomas
López‐García, M. Á., & Palacios, J. (2010) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2010.09.005 · Cited by 76
Chiyoda, T., Tsuda, H., Tanaka, H., Kataoka, F., Nomura, H., Nishimura, S., Takano, M., Susumu, N., Saya, H., & Aoki, D. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20947 · Cited by 65
Kareem, B. N., Karlsen, F., Holm, R., Hennig, E. M., Suo, Z., Emilsen, E., Hellesylt, E., & Nesland, J. M. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199712)183:4<424::aid-path949>3.0.co;2-l · Cited by 4
Cited by
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
“These clusters were also enriched for other Pan-gyn tumors, including ovarian, high-copy number endometrial, and uterine carcinosarcoma (Cherniack et al., 2017).”
BackgroundSelf-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Self-citationLu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Self-citationEndometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Berger, A. C., Korkut, A., Kanchi, R. S., Hegde, A. M., Lenoir, W., Liu, W., Liu, Y., Fan, H., Shen, H., Ravikumar, V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.014 · Cited by 620
Self-citation
Metadata
- Authors
- Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., Zuna, R. E., Robertson, G., Laird, P. W., Kucherlapati, R., Mills, G. B., Akbani, R., Ally, A., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., Beroukhim, R., Bodenheimer, T., Bogomolniy, F., Boice, L., Bootwalla, M. S., Bowen, J., Bowlby, R., Broaddus, R., Brooks, D., Carlsen, R., Cherniack, A. D., Cho, J., Chuah, E., Chudamani, S., Cibulskis, K., Cline, M., Dao, F., David, M., Demchok, J. A., Dhalla, N., Dowdy, S., Felau, I., Ferguson, M. L., Frazer, S., Frick, J., Gabriel, S., Gastier-Foster, J. M., Gehlenborg, N., Gerken, M., Getz, G., Gupta, M., Haussler, D., Hayes, D. N., Heiman, D. I., Hess, J., Hoadley, K. A., Hoffmann, R., Holt, R. A., Hoyle, A. P., Hu, X., Huang, M., Hutter, C. M., Jefferys, S. R., Jones, S. J. M., Jones, C. D., Kanchi, R. S., Kandoth, C., Kasaian, K., Kerr, S., Kim, J., Lai, P. H., Laird, P. W., Lander, E., Lawrence, M. S., Lee, D., Leraas, K. M., Leshchiner, I., Levine, D. A., Lichtenberg, T. M., Lin, P., Ling, S., Liu, J., Liu, W., Liu, Y., Lolla, L., Lu, Y., Ma, Y., Maglinte, D. T., Marra, M. A., Mayo, M., Meng, S., Meyerson, M., Mieczkowski, P. A., Mills, G. B., Moore, R. A., Mose, L. E., Mungall, A. J., Mungall, K., Murray, B. A., Naresh, R., Noble, M. S., Olvera, N., Parker, J. S., Perou, C. M., Perou, A. H., Pihl, T., Radenbaugh, A. J., Ramirez, N. C., Rathmell, W. K., Roach, J., Robertson, A. G., Sadeghi, S., Saksena, G., Salvesen, H. B., Schein, J. E., Schumacher, S. E., Shen, H., Sheth, M., Shi, Y., Shih, J., Simons, J. V., Sipahimalani, P., Skelly, T., Sofia, H. J., Soloway, M. G., Soslow, R. A., Sougnez, C., Stewart, C., Sun, C., Tam, A., Tan, D., Tarnuzzer, R., Thiessen, N., Thorne, L. B., Tse, K., Tseng, J., Van Den Berg, D. J., Veluvolu, U., Verhaak, R. G. W., Voet, D., von Bismarck, A., Walter, V., Wan, Y., Wang, Z., Wang, C., Weinstein, J. N., Weisenberger, D. J., Wilkerson, M. D., Winterhoff, B., Wise, L., Wong, T., Wu, Y., Yang, L., Zenklusen, J. C., Zhang, J. (., Zhang, H., Zhang, W., Zhu, J.-C., Zmuda, E., Zuna, R. E., Weinstein, J. N., Zhang, J., Akbani, R., & Levine, D. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 31
- Issue
- 3
- Pages
- 411-423
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2595991414
- Cited by
- 434
- References
- 40
- FWCI
- 40.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.